195 related articles for article (PubMed ID: 37256126)
1. Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins.
Pan S; Zhao W; Li Y; Ying Z; Luo Y; Wang Q; Li X; Lu W; Dong X; Wu Y; Wu X
Front Immunol; 2023; 14():1189161. PubMed ID: 37256126
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study.
Li B; Wang Q; Luo Y; Wang S; Pan S; Zhao W; Ye Z; Wu X
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730580
[TBL] [Abstract][Full Text] [Related]
3. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.
Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
Front Immunol; 2022; 13():887916. PubMed ID: 35874720
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
5. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
8. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
9. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer.
Zhou Z; Zhang J; Xu C; Yang J; Zhang Y; Liu M; Shi X; Li X; Zhan H; Chen W; McNally LR; Fung KM; Luo W; Houchen CW; He Y; Zhang C; Li M
EBioMedicine; 2021 Mar; 65():103271. PubMed ID: 33714027
[TBL] [Abstract][Full Text] [Related]
10. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
11. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
12. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
14. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma.
Chen Y; Zou X; Ma M; Liu Y; Wang R; Dai Z; Tashiheng Y; Yan Y; Yu X; Wang X; Liu C; Lin X; Cheng H
Curr Oncol; 2023 Jan; 30(2):1648-1662. PubMed ID: 36826087
[TBL] [Abstract][Full Text] [Related]
15. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
16. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
Front Immunol; 2021; 12():719105. PubMed ID: 35111149
[TBL] [Abstract][Full Text] [Related]
17. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
19. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
20. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]